Missense mutations in the perforin (PRF1) gene as a cause of hereditary cancer predisposition

References

• Law RHP, Lukoyanova N, Voskoboinik I, Caradoc-Davies TT, Baran K, Dunstone MA, D'Angelo ME, Orlova EV, Coulibaly F, Verschoor S et al. The structural basis for membrane binding and pore formation by lymphocyte perforin. Nature 2010; 468:447-U277; PMID:21037563; http://dx.doi.org/10.1038/nature09518
   PubMed Web of Science ®Google Scholar
• de Saint-Basile G, Menasche G, Fischer A. Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules. Nat Rev Immunol 2010; 10:568-79; PMID:20634814; http://dx.doi.org/10.1038/nri2803
   PubMed Web of Science ®Google Scholar
• Lopez JA, Susanto O, Jenkins MR, Lukoyanova N, Sutton VR, Law RHP, Johnston A, Bird CH, Bird PI, Whisstock JC et al. Perforin forms transient pores on the target cell plasma membrane to facilitate rapid access of granzymes during killer cell attack. Blood 2013; 121:2659-68; PMID:23377437; http://dx.doi.org/10.1182/blood-2012-07-446146
   PubMed Web of Science ®Google Scholar
• Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain S, Mathew PA, Henter JI, Bennett M, Fischer A, de Saint Basile G et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999; 286:1957-9; PMID:10583959; http://dx.doi.org/10.1126/science.286.5446.1957
   PubMed Web of Science ®Google Scholar
• Molleran Lee S, Villanueva J, Sumegi J, Zhang K, Kogawa K, Davis J, Filipovich AH. Characterisation of diverse PRF1 mutations leading to decreased natural killer cell activity in North American families with haemophagocytic lymphohistiocytosis. J Med Genet 2004; 41:137-44; PMID:14757862; http://dx.doi.org/10.1136/jmg.2003.013003
   PubMed Web of Science ®Google Scholar
• Voskoboinik I, Trapani JA. Perforinopathy: a spectrum of human immune disease caused by defective perforin delivery or function. Front Immunol 2013; 4:441-1; PMID:24376445; http://dx.doi.org/10.3389/fimmu.2013.00441
   PubMed Web of Science ®Google Scholar
• Nagafuji K, Nonami A, Kumano T, Kikushige Y, Yoshimoto G, Takenaka K, Shimoda K, Ohga S, Yasukawa M, Horiuchi H et al. Perforin gene mutations in adult-onset hemophagocytic lymphohistiocytosis. Haematologica 2007; 92:978-81; PMID:17606450; http://dx.doi.org/10.3324/haematol.11233
   PubMed Web of Science ®Google Scholar
• Clementi R, Locatelli F, Dupré L, Garaventa A, Emmi L, Bregni M, Cefalo G, Moretta A, Danesino C, Comis M et al. A proportion of patients with lymphoma may harbor mutations of the perforin gene. Blood 2005; 105:4424-8; PMID:15728124; http://dx.doi.org/10.1182/blood-2004-04-1477
   PubMed Web of Science ®Google Scholar
• Muralitharan S, Wali Y, Pathare AV. Perforin A91V polymorphism and putative susceptibility to hematological malignancies. Leukemia 2006; 20:2178; PMID:17039227; http://dx.doi.org/10.1038/sj.leu.2404433
   PubMed Web of Science ®Google Scholar
• Cannella S, Santoro A, Bruno G, Pillon M, Mussolin L, Mangili G, Rosolen A, Aric∫ M. Germline mutations of the perforin gene are a frequent occurrence in childhood anaplastic large cell lymphoma. Cancer 2007; 109:2566-71; PMID:17477373; http://dx.doi.org/10.1002/cncr.22718
   PubMed Web of Science ®Google Scholar
• Chia J, Yeo KP, Whisstock JC, Dunstone MA, Trapani JA, Voskoboinik I. Temperature sensitivity of human perforin mutants unmasks subtotal loss of cytotoxicity, delayed FHL, and a predisposition to cancer. Proc Natl Acad Sci USA 2009; 106:9809-14; PMID:19487666; http://dx.doi.org/10.1073/pnas.0903815106
   PubMed Web of Science ®Google Scholar
• Trapani JA, Thia KYT, Andrews M, Davis ID, Gedye C, Parente P, Svobodova S, Chia J, Browne K, Campbell IG et al. Human perforin mutations and susceptibility to multiple primary cancers. Oncoimmunology 2013; 2:e24185; PMID:23734337; http://dx.doi.org/10.4161/onci.24185
   PubMedGoogle Scholar
• Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. J Immunol 2012; 188:2046-56; PMID:22345701; http://dx.oi.org/10.1016/0092-8674(94)90169-4
   PubMed Web of Science ®Google Scholar
• Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353:2477-90; PMID:16339096; http://dx.doi.org/10.1056/NEJMra043172
   PubMed Web of Science ®Google Scholar
• Vauléon E, Tony A, Hamlat A, Etcheverry A, Chiforeanu DC, Menei P, Mosser J, Quillien V, Aubry M. Immune genes are associated with human glioblastoma pathology and patient survival. BMC Med Genomics 2012; 5:41; PMID:22980038; http://dx.doi.org/10.1186/1755-8794-5-41
   PubMed Web of Science ®Google Scholar
• Trambas C, Gallo F, Pende D, Marcenaro S, Moretta L, De Fusco C, Santoro A, Notarangelo L, Aric∫ M, Griffiths GM. A single amino acid change, A91V, leads to conformational changes that can impair processing to the active form of perforin. Blood 2005; 106:932-7; PMID:15741215; http://dx.doi.org/10.1182/blood-2004-09-3713
   PubMed Web of Science ®Google Scholar
• House IG, Thia K, Brennan AJ, Tothill R, Dobrovic A, Yeh WZ, Saffery R, Chatterton Z, Trapani JA, Voskoboinik I. Heterozygosity for the common perforin mutation, p.A91V, impairs the cytotoxicity of primary natural killer cells from healthy individuals. Immunol Cell Biol 2015; 93:575-80; PMID:25776844; http://dx.doi.org/10.1038/icb.2015.1
   PubMed Web of Science ®Google Scholar
• Mancebo E, Allende LM, Guzmán M, Paz-Artal E, Gil J, Urrea-Moreno R, Fernández-Cruz E, Gayà A, Calvo J, Arbós A et al. Familial hemophagocytic lymphohistiocytosis in an adult patient homozygous for A91V in the perforin gene, with tuberculosis infection. Haematologica 2006; 91:1257-60; PMID:16956828
   PubMed Web of Science ®Google Scholar
• Burnet FM. Immunological Surveillance in Neoplasia. Immunol Rev 1971; 7:3-25; PMID:5146537; http://dx.doi.org/10.1111/j.1600-065X.1971.tb00461.x
   Google Scholar
• Smyth MJ, Thia KY, Cretney E, Kelly JM, Snook MB, Forbes CA, Scalzo AA. Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol 1999; 162:6658-62; PMID:10352283
   PubMed Web of Science ®Google Scholar
• Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001; 97:192-7; PMID:11133760; http://dx.doi.org/10.1182/blood.V97.1.192
   PubMed Web of Science ®Google Scholar
• Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol 2005; 23:276-92; PMID:15637391; http://dx.doi.org/10.1200/JCO.2005.10.042
   PubMed Web of Science ®Google Scholar
• Löfstedt A, Chiang SCC, Onelöv E, Bryceson YT, Meeths M, Henter J-I. Cancer risk in relatives of patients with a primary disorder of lymphocyte cytotoxicity: a retrospective cohort study. Lancet Haematol 2015; 2:e536-42; PMID:26686408; http://dx.doi.org/10.1016/S2352-3026(15)00223-9
   PubMedGoogle Scholar
• Voskoboinik I, Sutton VR, Ciccone A, House CM, Chia J, Darcy PK, Yagita H, Trapani JA. Perforin activity and immune homeostasis: the common A91V polymorphism in perforin results in both presynaptic and postsynaptic defects in function. Blood 2007; 110:1184-90; PMID:17475905; http://dx.doi.org/10.1182/blood-2007-02-072850
   PubMed Web of Science ®Google Scholar
• Zhang K, Chandrakasan S, Chapman H, Valencia CA, Husami A, Kissell D, Johnson JA, Filipovich AH. Synergistic defects of different molecules in the cytotoxic pathway lead to clinical familial hemophagocytic lymphohistiocytosis. Blood 2014; 124:1331-4; PMID:24916509; http://dx.doi.org/10.1182/blood-2014-05-573105
   PubMed Web of Science ®Google Scholar